CircoMax Myco Union européenne - islandais - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - Ónæmissjúkdómar fyrir suidae - svín (fyrir fitandi) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Amversio Union européenne - islandais - EMA (European Medicines Agency)

amversio

serb sa - betaine - homocystinuria - Önnur meltingarvegi og efnaskipti vörur, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (cbs),•         5,10 methylene tetrahydrofolate reductase (mthfr),•         cobalamin cofactor metabolism (cbl).

FOMEPIZOLE SERB (Fomepizole EUSA Pharma) Innrennslisþykkni, lausn 5 mg/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

fomepizole serb (fomepizole eusa pharma) innrennslisþykkni, lausn 5 mg/ml

serb s.a. - fomepizolum súlfat - innrennslisþykkni, lausn - 5 mg/ml

Dexól Saft 3 mg/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

dexól saft 3 mg/ml

laboratoria qualiphar - dextromethorphanum hýdróbrómíð mónóhýdrat - saft - 3 mg/ml

Alvegesic vet. Stungulyf, lausn 10 mg/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

alvegesic vet. stungulyf, lausn 10 mg/ml

v.m.d. n.v. - butorphanolum tartrat - stungulyf, lausn - 10 mg/ml

Calci-kel vet. Kela Innrennslislyf, lausn 20,8 mg Ca/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

calci-kel vet. kela innrennslislyf, lausn 20,8 mg ca/ml

kela - kempisch laboratorium - kela laboratoria - calcii gluconas - innrennslislyf, lausn - 20,8 mg ca/ml

Gentacoll Vefjalyf 1,3 mg/cm2 Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

gentacoll vefjalyf 1,3 mg/cm2

serb s.a. - gentamicinum súlfat - vefjalyf - 1,3 mg/cm2

Thiamine Sterop Stungulyf, lausn 50 mg/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

thiamine sterop stungulyf, lausn 50 mg/ml

laboratoires sterop nv - thiaminum hýdróklóríð - stungulyf, lausn - 50 mg/ml

Túfen Saft 13,33 mg/ml Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

túfen saft 13,33 mg/ml

laboratoria qualiphar - guaifenesinum inn - saft - 13,33 mg/ml

Arexvy Union européenne - islandais - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.